Directed Therapies in Lung Cancer: New Hope?

被引：3

作者：

Parente Lamelas, Isaura ^{[1
]}

Abal Arca, Jose ^{[1
]}

Firvida Perez, Jose Luis ^{[2
]}

机构：

[1] Complexo Hosp Univ Ourense, Serv Neumol, Orense, Spain

[2] Complexo Hosp Univ Ourense, Med Oncol Serv, Orense, Spain

来源：

ARCHIVOS DE BRONCONEUMOLOGIA | 2012年 / 48卷 / 10期

关键词：

Lung cancer; Epidermal growth factor receptor; Vascular endothelial growth factor; Anaplastic lymphoma kinase; Erlotinib; Gefitinib; Bevacizumab; Crizotinib; GROWTH-FACTOR-RECEPTOR; EML4-ALK FUSION GENE; PHASE-III; OPEN-LABEL; 1ST-LINE THERAPY; GEFITINIB; MUTATIONS; SURVIVAL; ERLOTINIB; CHEMOTHERAPY;

D O I：

10.1016/j.arbres.2012.03.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK). (c) 2011 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.

引用

页码：367 / 371

页数：5

共 50 条

[31] Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer
Yang, Szu-Chun
Lin, Chien-Chung
Lai, Wu-Wei
Chang, Sheng-Mao
Hwang, Jing-Shiang
Su, Wu-Chou
Wang, Jung-Der
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[32] Developments in systemic therapies for the management of lung cancer
Heynemann, Sarah
Mitchell, Paul
INTERNAL MEDICINE JOURNAL, 2021, 51 (12) : 2012 - 2020
[33] Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country
Hernandez-Martinez, Juan-Manuel
Guijosa, Alberto
Flores-Estrada, Diana
Cruz-Rico, Graciela
Turcott, Jenny
Hernandez-Pedro, Norma
Caballe-Perez, Enrique
Cardona, Andres F.
Arrieta, Oscar
JCO GLOBAL ONCOLOGY, 2024, 10
[34] How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?
Coate, Linda E.
Leighl, Natasha B.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2011, 12 (01) : 1 - 11
[35] Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Shen, Peng
Zhong, Wenzhao
JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1364 - 1369
[36] ALK in Lung Cancer: Past, Present, and Future
Shaw, Alice T.
Engelman, Jeffrey A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 1105 - 1111
[37] Targeted therapy: An evolving world of lung cancer
Lam, Kwok-Chi
Mok, Tony S.
RESPIROLOGY, 2011, 16 (01) : 13 - 21
[38] KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non-Small Cell Lung Cancer Clues For Its Potential Use in Second-Line Therapy Decision Making
Campos-Parra, Alma D.
Zuloaga, Carlos
Vazquez Manriquez, Maria Eugenia
Aviles, Alejandro
Borbolla-Escoboza, Jose
Cardona, Andres
Meneses, Abelardo
Arrieta, Oscar
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (01): : 33 - 40
[39] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
Lange, Ansgar
Prenzler, Anne
Frank, Martin
Golpon, Heiko
Welte, Tobias
von der Schulenburg, J-Matthias
BMC PULMONARY MEDICINE, 2014, 14
[40] Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer
Ying, Hongyan
Yang, Xian-Da
Sun, Zhao
Ning, Xiaohong
Wang, Yingyi
Bai, Chunmai
Chen, Shuchang
Wang, Yuzhou
MEDICAL ONCOLOGY, 2014, 31 (10) : 1 - 7

← 1 2 3 4 5 →